{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T09:08:58Z","timestamp":1764493738763},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1,1]]},"abstract":"<jats:p>Histiocytosis, including the coexistence of Langerhans' cell histiocytosis and Erdheim-Chester disease, is discussed.<\/jats:p>","DOI":"10.1634\/theoncologist.2012-0440","type":"journal-article","created":{"date-parts":[[2013,1,9]],"date-time":"2013-01-09T14:04:12Z","timestamp":1357740252000},"page":"2-4","source":"Crossref","is-referenced-by-count":9,"title":["A Tale of Two Histiocytic Disorders"],"prefix":"10.1093","volume":"18","author":[{"given":"Filip","family":"Janku","sequence":"first","affiliation":[{"name":"a Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Munoz","sequence":"additional","affiliation":[{"name":"a Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[{"name":"a Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[{"name":"b Moores Cancer Center, The University of California San Diego, San Diego, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2013,1,8]]},"reference":[{"key":"2021122308260060500_B1","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nrc1632","article-title":"The Nikolas Symposia and histiocytosis","volume":"5","author":"Beverley","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"2021122308260060500_B2","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"2021122308260060500_B3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/BOR.0b013e32834db53e","article-title":"Langerhans cell histiocytosis and Erdheim-Chester disease","volume":"24","author":"Wilejto","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"2021122308260060500_B4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/WNO.0b013e31820a204e","article-title":"Presence of Erdheim-Chester disease and Langerhans cell histiocytosis in the same patient: A report of 2 cases","volume":"31","author":"Pineles","year":"2011","journal-title":"J Neuroophthalmol"},{"key":"2021122308260060500_B5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/BOR.0b013e32834d861d","article-title":"Erdheim-Chester disease","volume":"24","author":"Haroche","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"2021122308260060500_B6","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","article-title":"Recurrent BRAF mutations in Langerhans cell histiocytosis","volume":"116","author":"Badalian-Very","year":"2010","journal-title":"Blood"},{"key":"2021122308260060500_B7","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2012-05-430140","article-title":"High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses","volume":"120","author":"Haroche","year":"2012","journal-title":"Blood"},{"key":"2021122308260060500_B8","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1182\/blood-2010-06-294108","article-title":"CNS involvement and treatment with interferon-\u03b1 are independent prognostic factors in Erdheim-Chester disease: A multicenter survival analysis of 53 patients","volume":"117","author":"Arnaud","year":"2011","journal-title":"Blood"},{"key":"2021122308260060500_B9","doi-asserted-by":"crossref","first-page":"e633","DOI":"10.1200\/JCO.2010.29.9073","article-title":"Response of histiocytoses to imatinib mesylate: Fire to ashes","volume":"28","author":"Janku","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308260060500_B10","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1517\/14656566.2012.688028","article-title":"Medical management of Langerhans cell histiocytosis from diagnosis to treatment","volume":"13","author":"Donadieu","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"2021122308260060500_B11","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ctrv.2010.02.012","article-title":"Langerhans cell histiocytosis: Current concepts and treatments","volume":"36","author":"Abla","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"2021122308260060500_B12","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1182\/blood-2005-06-2238","article-title":"Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-\u03b1","volume":"106","author":"Braiteh","year":"2005","journal-title":"Blood"},{"key":"2021122308260060500_B13","doi-asserted-by":"crossref","first-page":"5413","DOI":"10.1182\/blood-2008-03-148304","article-title":"Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis","volume":"111","author":"Haroche","year":"2008","journal-title":"Blood"},{"key":"2021122308260060500_B14","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.semarthrit.2011.11.004","article-title":"Treatment of Erdheim-Chester disease with long-term high-dose interferon-\u03b1","volume":"41","author":"Hervier","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"2021122308260060500_B15","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1182\/blood-2010-04-279240","article-title":"Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease","volume":"116","author":"Aouba","year":"2010","journal-title":"Blood"},{"key":"2021122308260060500_B16","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0002-9394(01)01141-2","article-title":"Interferon therapy for orbital infiltration secondary to Erdheim-Chester disease","volume":"132","author":"Esmaeli","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"2021122308260060500_B17","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1200\/JCO.2012.41.9911","article-title":"Tumor necrosis factor \u03b1 as a master regulator of inflammation in Erdheim-Chester disease: Rationale for the treatment of patients with infliximab","volume":"30","author":"Dagna","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122308260060500_B18","first-page":"313","article-title":"[Interleukin-1 receptor blockade with anakinra provided cessation of fatigue, reduction in inflammation markers and regression of retroperitoneal fibrosis in a patient with Erdheim-Chester disease\u2014case study and a review of literature]","volume":"58","author":"Adam","year":"2012","journal-title":"Vnitr Lek"},{"key":"2021122308260060500_B19","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1067\/mpd.2001.111331","article-title":"A randomized trial of treatment for multisystem Langerhans' cell histiocytosis","volume":"138","author":"Gadner","year":"2001","journal-title":"J Pediatr"},{"key":"2021122308260060500_B20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/mpo.2950230203","article-title":"Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group","volume":"23","author":"Gadner","year":"1994","journal-title":"Med Pediatr Oncol"},{"key":"2021122308260060500_B21","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1182\/blood-2007-08-106211","article-title":"Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification","volume":"111","author":"Gadner","year":"2008","journal-title":"Blood"},{"key":"2021122308260060500_B22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1634\/theoncologist.2012-0234","article-title":"Hand-Sch\u00fcller-Christian Disease and Erdheim-Chester Disease: Coexistence and Discrepancy","volume":"18","author":"Yin","year":"2013","journal-title":"The Oncologist"},{"key":"2021122308260060500_B23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/00005792-199605000-00005","article-title":"Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases","volume":"75","author":"Veyssier-Belot","year":"1996","journal-title":"Medicine (Baltimore)"},{"key":"2021122308260060500_B24","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1056\/NEJM200409023511022","article-title":"Imatinib mesylate for cerebral Langerhans'-cell histiocytosis","volume":"351","author":"Montella","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122308260060500_B25","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/archdermatol.2008.597","article-title":"A case of cutaneous Rosai-Dorfman disease refractory to imatinib therapy","volume":"145","author":"Gebhardt","year":"2009","journal-title":"Arch Dermatol"},{"key":"2021122308260060500_B26","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/archderm.143.6.736","article-title":"Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses","volume":"143","author":"Utikal","year":"2007","journal-title":"Arch Dermatol"},{"key":"2021122308260060500_B27","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood-2003-03-0975","article-title":"Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells","volume":"103","author":"Appel","year":"2004","journal-title":"Blood"},{"key":"2021122308260060500_B28","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1200\/JCO.2012.43.2260","article-title":"Erdheim-Chester disease harboring the BRAF V600E mutation","volume":"20","author":"Blombery","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122308260060500_B29","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122308260060500_B30","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dab-rafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"},{"key":"2021122308260060500_B31","article-title":"Rapid response to vemurafenib in a heavily-pretreated patient with hairy cell leukemia and a BRAF mutation","author":"Munoz","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/pdf\/10.1634\/theoncologist.2012-0440","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/full-xml\/10.1634\/theoncologist.2012-0440","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/1\/2\/41856027\/oncolo_18_1_2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/1\/2\/41856027\/oncolo_18_1_2.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T22:47:46Z","timestamp":1640299666000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/18\/1\/2\/6410162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1,8]]},"published-print":{"date-parts":[[2013,1,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2012-0440","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,1,1]]},"published":{"date-parts":[[2013,1,1]]}}}